Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 28, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Cap	13	59	71	60	121	159
Market Cap Growth	-89.73%	-16.43%	17.53%	-50.38%	-23.75%	-
Enterprise Value	4.42	47.53	67.7	48.99	106.84	139.22

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 28, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
PB Ratio	1.70	5.07	18.57	5.68	8.06	7.44

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 28, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Debt / Equity Ratio	-1.14	-1.00	-0.81	-1.06	-0.97	-0.93
Net Debt / EBITDA Ratio	1.03	1.32	0.38	0.95	2.13	5.53
Net Debt / FCF Ratio	1.55	1.83	0.38	1.16	2.68	4.10
Quick Ratio	6.12	23.99	11.87	10.52	28.39	82.71
Current Ratio	6.24	24.53	13.46	10.92	30.40	89.61
Return on Equity (ROE)	-69.69%	-109.69%	-113.80%	-91.42%	-37.42%	-249.85%
Return on Assets (ROA)	-72.07%	-113.74%	-105.55%	-86.49%	-36.69%	-29.28%
Return on Invested Capital (ROIC)	1595.31%	-2464.82%	-22991.10%	18466.12%	-702.56%	-513.63%
Return on Capital Employed (ROCE)	-79.51%	-119.24%	-115.29%	-91.81%	-37.45%	-29.85%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 28, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Buyback Yield / Dilution	-55.97%	-30.97%	-2.98%	-7.41%	-71.49%	-13.44%
Total Shareholder Return	-55.97%	-30.97%	-2.98%	-7.41%	-71.49%	-13.44%

Data Source: Fiscal.ai Last updated: Dec 31, 2025

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error